CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Sage Therapeutics, Inc. - SAGE CFD

19.20
1.69%
Market Trading Hours* (UTC) Opens on Tuesday at 13:30

Mon - Fri: 13:30 - 20:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.11
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026151 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026151%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003929 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003929%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

SAGE Therapeutics Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 19.53
Open* 19.2
1-Year Change* -49.93%
Day's Range* 19.1 - 19.49
52 wk Range 16.52-59.99
Average Volume (10 days) 956.99K
Average Volume (3 months) 32.86M
Market Cap 1.25B
P/E Ratio -100.00K
Shares Outstanding 59.88M
Revenue 10.37M
EPS -9.93
Dividend (Yield %) N/A
Beta 1.13
Next Earnings Date Nov 6, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Sep 25, 2023 19.20 0.03 0.16% 19.17 19.53 19.09
Sep 22, 2023 19.53 0.06 0.31% 19.47 19.82 19.27
Sep 21, 2023 19.55 -0.03 -0.15% 19.58 19.69 19.17
Sep 20, 2023 19.86 -0.35 -1.73% 20.21 20.44 19.77
Sep 19, 2023 20.38 0.12 0.59% 20.26 20.61 19.96
Sep 18, 2023 20.24 -0.72 -3.44% 20.96 20.96 19.92
Sep 15, 2023 20.95 -0.39 -1.83% 21.34 21.53 20.48
Sep 14, 2023 21.44 -1.14 -5.05% 22.58 23.08 21.10
Sep 13, 2023 22.58 -0.79 -3.38% 23.37 23.80 22.40
Sep 12, 2023 23.38 1.99 9.30% 21.39 23.53 21.39
Sep 11, 2023 21.60 0.14 0.65% 21.46 22.12 21.30
Sep 8, 2023 21.55 0.90 4.36% 20.65 21.76 20.38
Sep 7, 2023 20.77 0.39 1.91% 20.38 21.04 20.12
Sep 6, 2023 20.58 0.19 0.93% 20.39 20.88 20.29
Sep 5, 2023 20.49 0.50 2.50% 19.99 20.61 19.56
Sep 1, 2023 20.24 0.29 1.45% 19.95 20.61 19.88
Aug 31, 2023 19.96 0.40 2.04% 19.56 20.38 19.56
Aug 30, 2023 19.66 -0.03 -0.15% 19.69 20.13 19.36
Aug 29, 2023 19.80 0.23 1.18% 19.57 20.15 19.51
Aug 28, 2023 19.87 0.28 1.43% 19.59 20.07 19.48

Sage Therapeutics, Inc. Events

Time (UTC) Country Event
Monday, November 6, 2023

Time (UTC)

13:30

Country

US

Event

Q3 2023 SAGE Therapeutics Inc Earnings Release
Q3 2023 SAGE Therapeutics Inc Earnings Release

Forecast

-

Previous

-
Wednesday, February 14, 2024

Time (UTC)

13:30

Country

US

Event

Q4 2023 SAGE Therapeutics Inc Earnings Release
Q4 2023 SAGE Therapeutics Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 7.686 6.308 1114.2 6.868 90.273
Total Operating Expense 554.675 467.217 517.974 714.992 483.511
Selling/General/Admin. Expenses, Total 227.699 183.498 196.952 345.777 201.404
Research & Development 326.163 283.166 292.714 368.815 282.107
Operating Income -546.989 -460.909 596.226 -708.124 -393.238
Interest Income (Expense), Net Non-Operating 14.19 2.883 9.597 27.804 20.334
Other, Net 0.015 0.134 0.25 0.082 0.022
Net Income Before Taxes -532.784 -457.892 606.073 -680.238 -372.882
Net Income After Taxes -532.784 -457.892 606.073 -680.238 -372.882
Net Income Before Extra. Items -532.784 -457.892 606.073 -680.238 -372.882
Net Income -532.784 -457.892 606.073 -680.238 -372.882
Income Available to Common Excl. Extra. Items -532.784 -457.892 606.073 -680.238 -372.882
Income Available to Common Incl. Extra. Items -532.784 -457.892 606.073 -680.238 -372.882
Diluted Net Income -532.784 -457.892 606.073 -680.238 -372.882
Diluted Weighted Average Shares 59.3061 58.6702 53.0031 50.8338 46.1212
Diluted EPS Excluding Extraordinary Items -8.98363 -7.8045 11.4347 -13.3816 -8.08483
Diluted Normalized EPS -8.98363 -7.8045 11.9581 -13.3816 -8.08483
Total Extraordinary Items
Revenue 7.686 6.308 1114.2 6.868 90.273
Cost of Revenue, Total 0.813 0.553 0.565 0.4
Gross Profit 6.873 5.755 1113.64 6.468
Unusual Expense (Income) 0 0 27.743
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 2.474 3.294 2.865 1.739 1.501
Revenue 2.474 3.294 2.865 1.739 1.501
Cost of Revenue, Total 0.205 0.23 0.143 0.184 0.2
Gross Profit 2.269 3.064 2.722 1.555 1.301
Total Operating Expense 172.931 158.764 156.767 143.219 129.908
Selling/General/Admin. Expenses, Total 75.565 65.708 67.329 61.482 52.411
Research & Development 97.161 92.826 89.295 81.553 77.297
Operating Income -170.457 -155.47 -153.902 -141.48 -128.407
Interest Income (Expense), Net Non-Operating 10.173 8.83 6.793 4.127 2.102
Other, Net -0.041 -0.188 -0.037 0.03 0.045
Net Income Before Taxes -160.325 -146.828 -147.146 -137.323 -126.26
Net Income After Taxes -160.325 -146.828 -147.146 -137.323 -126.26
Net Income Before Extra. Items -160.325 -146.828 -147.146 -137.323 -126.26
Net Income -160.325 -146.828 -147.146 -137.323 -126.26
Income Available to Common Excl. Extra. Items -160.325 -146.828 -147.146 -137.323 -126.26
Income Available to Common Incl. Extra. Items -160.325 -146.828 -147.146 -137.323 -126.26
Diluted Net Income -160.325 -146.828 -147.146 -137.323 -126.26
Diluted Weighted Average Shares 59.7696 59.6741 59.4967 59.4281 59.2663
Diluted EPS Excluding Extraordinary Items -2.68238 -2.4605 -2.47318 -2.31074 -2.13038
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -2.68238 -2.4605 -2.47318 -2.31074 -2.13038
Unusual Expense (Income) 0
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 1336.98 1800.64 2122.37 1035.09 944.695
Cash and Short Term Investments 1272.49 1742.3 2099.55 1008.39 922.776
Cash & Equivalents 162.7 294.233 1661.08 126.705 190.943
Short Term Investments 1109.79 1448.06 438.467 881.688 731.833
Prepaid Expenses 50.826 39.841 22.821 26.7 21.919
Total Assets 1356.45 1825.29 2159.25 1084.15 952.705
Property/Plant/Equipment, Total - Net 13.43 19.125 31.819 42.897 5.643
Property/Plant/Equipment, Total - Gross 19.525 24.098 38.907 47.396 7.859
Accumulated Depreciation, Total -6.095 -4.973 -7.088 -4.499 -2.216
Other Long Term Assets, Total 6.039 5.52 5.057 6.16 2.367
Total Current Liabilities 99.259 85.193 67.204 112.128 86.03
Accounts Payable 18.95 10.45 3.691 15.266 34.036
Accrued Expenses 37.572 26.703 23.931 33.202 19.875
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 42.737 48.04 39.582 63.66 32.119
Total Liabilities 103.85 96.257 86.912 139.495 89.734
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 4.591 11.064 19.708 27.367 3.704
Total Equity 1252.6 1729.03 2072.33 944.655 862.971
Redeemable Preferred Stock 0 0 0 0
Common Stock 0.006 0.006 0.006 0.005 0.005
Additional Paid-In Capital 3291.37 3227.47 3109.81 2587.32 1827.02
Retained Earnings (Accumulated Deficit) -2028.17 -1495.39 -1037.49 -1643.57 -963.329
Treasury Stock - Common -0.4 -0.4 -0.4 -0.4 -0.211
Other Equity, Total -10.206 -2.66 0.415 1.295 -0.515
Total Liabilities & Shareholders’ Equity 1356.45 1825.29 2159.25 1084.15 952.705
Total Common Shares Outstanding 59.5091 58.937 58.3084 51.8772 46.8883
Total Receivables, Net 13.66 18.506
Accounts Receivable - Trade, Net 13.66 18.506
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total Current Assets 1203.44 1336.98 1465.1 1578.88 1682.24
Cash and Short Term Investments 1129.58 1272.49 1393.64 1513.71 1625.24
Cash & Equivalents 206.557 162.7 199.826 206.51 178.674
Short Term Investments 923.028 1109.79 1193.81 1307.2 1446.57
Total Receivables, Net 15.002 13.66 18.448 23.722 19.797
Accounts Receivable - Trade, Net 15.002 13.66 18.448 23.722 19.797
Prepaid Expenses 58.85 50.826 53.017 41.455 37.206
Total Assets 1220.69 1356.45 1486.07 1601.38 1705.7
Property/Plant/Equipment, Total - Net 11.725 13.43 14.791 16.317 17.599
Property/Plant/Equipment, Total - Gross 19.525 22.847
Accumulated Depreciation, Total -6.095 -5.248
Other Long Term Assets, Total 5.524 6.039 6.178 6.176 5.86
Total Current Liabilities 84.692 99.259 99.687 89.241 77.703
Accounts Payable 12.263 18.95 7.077 5.41 7.129
Accrued Expenses 18.369 37.572 28.299 22.77 15.434
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 54.06 42.737 64.311 61.061 55.14
Total Liabilities 87.557 103.85 105.951 97.141 87.201
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 2.865 4.591 6.264 7.9 9.498
Total Equity 1133.13 1252.6 1380.12 1504.24 1618.5
Redeemable Preferred Stock 0 0 0
Common Stock 0.006 0.006 0.006 0.006 0.006
Additional Paid-In Capital 3313.61 3291.37 3276.42 3262.2 3247.54
Retained Earnings (Accumulated Deficit) -2175 -2028.17 -1881.02 -1743.7 -1617.44
Treasury Stock - Common -0.4 -0.4 -0.4 -0.4 -0.4
Other Equity, Total -5.088 -10.206 -14.883 -13.872 -11.201
Total Liabilities & Shareholders’ Equity 1220.69 1356.45 1486.07 1601.38 1705.7
Total Common Shares Outstanding 59.762 59.5091 59.4937 59.3887 59.0662
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -532.784 -457.892 606.073 -680.238 -372.882
Cash From Operating Activities -460.036 -378.182 664.28 -528.706 -260.671
Cash From Operating Activities 1.122 4.182 2.63 2.283 1.143
Non-Cash Items 65.955 94.034 95.306 142.591 91.856
Changes in Working Capital 5.671 -18.506 -39.729 6.658 19.212
Cash From Investing Activities 325.433 -1002.45 442.684 -143.156 -512.461
Capital Expenditures -0.937 -0.372 -0.345 -5.751 -2.86
Other Investing Cash Flow Items, Total 326.37 -1002.08 443.029 -137.405 -509.601
Cash From Financing Activities 3.07 13.334 426.762 607.624 659.358
Financing Cash Flow Items -0.043 -1.385 -2.503 -1.244
Issuance (Retirement) of Stock, Net 3.113 14.719 426.762 610.127 660.602
Net Change in Cash -131.533 -1367.3 1533.73 -64.238 -113.774
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -146.828 -532.784 -385.638 -248.315 -122.055
Cash From Operating Activities -153.682 -460.036 -333.104 -214.239 -107.8
Cash From Operating Activities 0.323 1.122 0.832 0.554 0.275
Non-Cash Items 16.83 65.955 52.076 37.849 20.897
Changes in Working Capital -24.007 5.671 -0.374 -4.327 -6.917
Cash From Investing Activities 194.867 325.433 235.656 124.704 -9.558
Other Investing Cash Flow Items, Total 195.092 326.37 236.311 124.995 -9.389
Cash From Financing Activities 2.672 3.07 3.041 1.812 1.799
Issuance (Retirement) of Stock, Net 3.301 3.113 3.08 1.836 1.799
Net Change in Cash 43.857 -131.533 -94.407 -87.723 -115.559
Capital Expenditures -0.225 -0.937 -0.655 -0.291 -0.169
Financing Cash Flow Items -0.629 -0.043 -0.039 -0.024
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Fidelity Management & Research Company LLC Investment Advisor 14.6778 8789617 1706204 2023-06-30 LOW
Wellington Management Company, LLP Investment Advisor/Hedge Fund 10.6266 6363630 649207 2023-06-30 LOW
Biogen Inc Corporation 10.4226 6241473 0 2023-03-31 HIGH
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 8.3815 5019202 53550 2023-06-30 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 5.9624 3570538 -11550 2023-06-30 LOW
Bellevue Asset Management AG Investment Advisor 5.2007 3114375 24375 2023-06-30 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 3.8393 2299140 -435233 2023-06-30 LOW
Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund 2.866 1716268 61568 2023-06-30 LOW
JP Morgan Asset Management Investment Advisor 1.857 1112064 291861 2023-06-30 LOW
Boxer Capital, L.L.C. Hedge Fund 1.8269 1094000 0 2023-06-30 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.7827 1067545 27300 2023-06-30 LOW
T. Rowe Price Associates, Inc. Investment Advisor 1.7505 1048295 -829697 2023-06-30 LOW
DWS Investment GmbH Investment Advisor/Hedge Fund 1.6699 1000000 300000 2023-06-30 LOW
Palo Alto Investors LP Hedge Fund 1.4353 859517 0 2023-06-30 LOW
Lord, Abbett & Co. LLC Investment Advisor 1.382 827577 637244 2023-06-30 MED
Marshall Wace LLP Investment Advisor/Hedge Fund 1.3335 798548 -613381 2023-06-30 HIGH
Columbia Threadneedle Investments (US) Investment Advisor/Hedge Fund 1.0796 646495 -228289 2023-06-30 LOW
Pictet Asset Management Ltd. Investment Advisor/Hedge Fund 1.0001 598918 592380 2023-06-30 LOW
Manulife Investment Management (North America) Limited Investment Advisor 0.9918 593938 -30733 2023-06-30 LOW
JPMorgan Asset Management U.K. Limited Investment Advisor/Hedge Fund 0.864 517402 26317 2023-06-30 LOW

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Sage Therapeutic Company profile

About SAGE Therapeutics Inc

SAGE Therapeutics, Inc. is a biopharmaceutical company that is focused on developing and commercializing medicines with debilitating disorders of the brain. The Company's product, ZULRESSO (brexanolone) CIV injection, is for the treatment of postpartum depression (PPD), in adults. The Company's products also include ZULRESSO (Brexanolone) CIV Injection, Zuranolone (SAGE-217), SAGE-324 and SAGE-718. Its next advanced product candidate is SAGE-217, is an oral compound that is in Phase III clinical development in PPD and depressive disorder (MDD). Zuranolone is a neuroactive steroid that, like brexanolone, is a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors. SAGE-324 is a GABAA receptor positive allosteric modulator intended for chronic oral dosing and conducting a placebo-controlled Phase II clinical trial evaluating the safety and efficacy of SAGE-324 in the treatment of essential tremor.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, SAGE Therapeutics Inc revenues decreased 99% to $6.3M. Net loss totaled $457.9M vs. income of $606.1M. Revenues reflect Collaboration revenue decrease from $1.11B to $0K, Product decrease of 6% to $6.3M. Net loss reflects Stock-based Compensation in R&D increase of 17% to $49.7M (expense), Stock-based Compensation in SGA increase of 6% to $54.9M (expense), Other income (expense).

Equity composition

Common Stock, $0.0001 Par, 07/14, auth. 120M shares,. 24,961,926 issd,. Insiders owns approx. 20.03%.

Industry: Bio Therapeutic Drugs

215 1st St
CAMBRIDGE
MASSACHUSETTS 02142
US

Income Statement

  • Annual
  • Quarterly

News

USD/JPY Climbs Towards Key Highs

USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.

11:32, 26 September 2023

EUR/USD tests key support

EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

14:32, 21 September 2023
Bank of England building

BoE leaves rates unchanged, GBP drops further as investors look for more clarity

The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

11:45, 21 September 2023
British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

GBP softer after CPI surprise, JPY focused on any further hints from Ueda

GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

12:42, 20 September 2023

How to Trade The Break & Retest

In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

11:59, 20 September 2023

Cable coils near lows ahead of Fed and BoE rate decisions

It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.

14:16, 19 September 2023

FTSE 100 Technical Outlook - 18 September 2023

In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.

06:55, 19 September 2023

People also watch

US100

14,665.30 Price
-0.740% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0039%
Overnight fee time 21:00 (UTC)
Spread 1.8

XRP/USD

0.51 Price
-0.320% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01192

Oil - Crude

89.11 Price
-0.860% 1D Chg, %
Long position overnight fee 0.0544%
Short position overnight fee -0.0763%
Overnight fee time 21:00 (UTC)
Spread 0.030

ETH/USD

1,588.72 Price
+0.010% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 5.40

Still looking for a broker you can trust?

Join the 555.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading